Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

INDUSTRY 4 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 11 Gastrointestinal 11 Gynecologic 8 Other hematologic neoplasm 6 Breast 6 Thoracic 5 Lymphoid 5 Genitourinary 5 Dermatologic 5 Head & Neck 4 Plasma cell 3 Other solid neoplasm 3 Sarcoma 2 Classical hematology 2 CNS 2 NET 1 Myeloid 1 Endocrine 1

Conditions

Intestinal Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 32 Everolimus 19 Magnetic Resonance Spectroscopy 14 gallium Ga 68 dotatate 12 Temozolomide 12 Nivolumab 11 Capecitabine 10 pembrolizumab 9 lanreotide 9 cabozantinib 8 Positron Emission Tomography Computed Tomography 8 177Lu-octreotide, DOTA(0)-Tyr(3)- 8 Ga(III)-DOTATOC 7 3-Iodobenzylguanidine 7 Somatostatin 6 Octreotide 6 Lutetium-177 6 Carboplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 telotristat ethyl 5 surufatinib 5 lenvatinib 5 Ipilimumab 5 Fluorodeoxyglucose F18 5 pasireotide 4 copper dotatate CU-64 4 avelumab 4 Single Photon Emission Computed Tomography Computed Tomography 4 Positron-Emission Tomography 4 Bevacizumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Data Collection × NET × Clear all

NCT06876532 2025-11-18

LUTIBI

Institut Claudius Regaud

Phase NA Recruiting

Intestinal Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡